Ground News

News from Cardiol Therapeutics

Your destination for news from Cardiol Therapeutics. See how Cardiol Therapeutics’s media bias impacts the breaking news stories of today.

In total, 6 have been published by Cardiol Therapeutics which Ground News has aggregated in the past 3 months.

The Ground News media bias check for Cardiol Therapeutics is unknown. Scores are assigned by aggregating bias scores from Ad Fontes Media, Media Bias/Fact Check, and All Sides.

We’ve assigned a rating of Unknown factuality to Cardiol Therapeutics. You can read more about how we’ve determined Cardiol Therapeutics’s credibility and reliability as a news source here: https://ground.news/rating-system.

Information about Cardiol Therapeutics

Where is Cardiol Therapeutics located?Cardiol Therapeutics's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Cardiol Therapeutics News

Ontario, Canada · Ontario

Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders

Toronto, ON – May 29, 2025 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its Annual General Meeting of Shareholders (the “AGM”) held virtually via live audio webcast on May 28, 2025. Shareholders voted overwhelmingly in favour of all Manage…Read Article

Ontario, Canada · Ontario

Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (‘Cardiol’ or the ‘Company’), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the Company’s virtual Annual General Meeting of Shareholders (the ‘AGM’) will be webcast on May 28, 2025, at 4:30 p.m. EDT. Cardiol Therapeutics’ 2025 AGM When: May 28, 2025, at 4:30 p.m. EDTWhere: Virtual me…See the Story

You've scrolled to the bottom of the feed, there are no more stories.

News from Cardiol Therapeutics